The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Honoraria - Amgen; Aspen Pharma; Bayer Schering Pharma; Bristol-Myers Squibb; Medac; Merck Serono; MSD; Roche Pharma AG; Sanofi; SERVIER; Shire
Consulting or Advisory Role - Amgen; Roche Pharma AG; Shire
Travel, Accommodations, Expenses - Ipsen; Medac; Merck Serono; PharmaMar
Ramucirumab, avelumab and paclitaxel (RAP) as second line treatment in esophagogastric adenocarcinoma: Final results of the phase 2 RAP trial (AIO-STO-0218).
 
Peter C. Thuss-Patience
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Meyers-Squibb; Daiichi Sankyo; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche; SERVIER
Research Funding - Merck/Pfizer (Inst)
 
Anica Högner
Consulting or Advisory Role - Bristol-Myers Squibb
 
Eray Goekkurt
Consulting or Advisory Role - Bristol-Myers Squibb; Daiichi Sankyo Europe GmbH; MSD Oncology; Pfizer; Roche Pharma AG
Travel, Accommodations, Expenses - SERVIER
 
Michael Stahl
Honoraria - Bristol-Myers Squibb/Medarex; MSD Oncology; Novartis/Pfizer; Roche/Genentech
Consulting or Advisory Role - BMS GmbH & Co. KG; Lilly/ImClone; MSD Oncology
 
Albrecht Kretzschmar
No Relationships to Disclose
 
Thorsten Oliver Goetze
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb; Foundation Medicine; Incyte; Lilly; MSD Oncology; Novartis; Roche; SERVIER
Speakers' Bureau - Lilly
Research Funding - AstraZeneca (Inst); Deutsche Forschungsgemeinschaft; Deutsche Krebshilfe (Inst); Gemeinsamer Bundesausschuss; Incyte (Inst); Lilly (Inst)
 
Gertraud Stocker
Consulting or Advisory Role - Bristol-Myers Squibb; SERVIER
 
Peter Reichardt
Honoraria - Boehringer Ingelheim (Inst); Clinigen Group (Inst); Deciphera (Inst); PharmaMar (Inst)
Consulting or Advisory Role - Bayer (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Deciphera (Inst); GlaxoSmithKline (Inst); Mundipharma (Inst); Novartis (Inst); PharmaMar (Inst); Roche (Inst)
Research Funding - Novartis (Inst)
 
Frank Kullmann
Consulting or Advisory Role - Bayer; Bristol-Myers Squibb/Celgene; MSD; Novartis; Pierre Fabre
Research Funding - Celgene (Inst)
 
Daniel Pink
Consulting or Advisory Role - Boehringer Ingelheim (Inst); Deciphera (Inst); PharmaMar (Inst)
Speakers' Bureau - PharmaMar (Inst)
Research Funding - Bristol-Myers Squibb (Inst); EUSA Pharma (Inst); PharmaMar (Inst); Roche (Inst)
 
Prisca Bartels
No Relationships to Disclose
 
Armin Jarosch
No Relationships to Disclose
 
Axel Hinke
Honoraria - Ipsen; Roche Pharma AG
 
Lisa Paschold
No Relationships to Disclose
 
Alexander Stein
Consulting or Advisory Role - Amgen (Inst); AstraZeneca; Bristol-Myers Squibb (Inst); Daiichi Sankyo/Astra Zeneca (Inst); Merck KGaA; MSD (Inst); Novartis (Inst); Roche; SERVIER (Inst)
Speakers' Bureau - Bristol-Myers Squibb (Inst); Merck KGaA; Roche; Sanofi; Servier
Research Funding - Bristol-Myers Squibb (Inst); Merck KGaA (Inst); MSD Oncology (Inst); Pierre Fabre (Inst); SERVIER (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck KGaA; Roche
 
Mascha Binder
Honoraria - Amgen; Janssen-Cilag; Merck; MSD
Consulting or Advisory Role - Janssen-Cilag; MSD
Research Funding - Janssen-Cilag; Novartis